Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2015-07-24 AGM Information
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
2015年第一次临时股东大会会议材料
AGM Information Classification · 95% confidence The document is titled as materials for the 2015 first extraordinary general meeting (临时股东大会) of 哈药集团股份有限公司. It contains detailed meeting agenda, voting procedures, and information about the election of directors. The content is focused on the meeting materials for a shareholder meeting, specifically related to board elections. There is no financial data or report content, but rather materials prepared for the meeting itself. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is short (2196 characters) and it is not an announcement of a report but the actual meeting materials. Therefore, the correct classification is AGM-R with high confidence.
2015-07-24 Chinese
七届八次监事会决议
Board/Management Information Classification · 90% confidence The document is a resolution from the supervisory board (监事会) of 哈药集团股份有限公司 regarding approval of a restricted stock incentive plan and related matters. It is a formal meeting decision document, not a financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. It is not an announcement of voting results at a general meeting (which would be DVA), but rather a board-level resolution. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies.
2015-07-20 Chinese
七届九次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's board meeting, specifically the 7th Board's 9th meeting. It details voting results on proposals related to a restricted stock incentive plan, including authorization for the board to handle related matters and the postponement of the shareholders' meeting. The document is an official announcement of board decisions and meeting outcomes, not a full report or financial statement. It does not contain financial data or detailed management discussion but rather the results of board deliberations and approvals. Therefore, it fits the category of Board/Management Information (MANG). The document length is short (2136 characters), consistent with an announcement rather than a full report.
2015-07-20 Chinese
限制性股票激励计划实施考核管理办法
Governance Information Classification · 95% confidence The document is titled as a management method for the implementation and assessment of a restricted stock incentive plan by 哈药集团股份有限公司 (Harbin Pharmaceutical Group Co., Ltd.). It details the purpose, principles, scope, assessment institutions, performance evaluation indicators, assessment periods, procedures, and feedback related to the stock incentive plan. The content focuses on governance and management of the stock incentive plan rather than financial results, audit, or regulatory announcements. It is a governance-related document outlining internal rules and procedures for performance assessment tied to stock incentives. The document length is 2295 characters, which is relatively short and does not contain financial statements or earnings data. It is not an announcement of a report but a detailed governance policy document. Therefore, the most appropriate classification is Governance Information (CGR).
2015-07-20 Chinese
七届八次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of 哈药集团股份有限公司 regarding approval of a restricted stock incentive plan and related matters. It includes voting results and compliance statements but does not contain financial statements or detailed financial data. It is a formal announcement of board/management decisions rather than a full report or financial disclosure. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board resolutions, not an annual or interim report or other categories.
2015-07-20 Chinese
独立董事关于公司限制性股票激励计划（草案）及摘要的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on a company's restricted stock incentive plan draft and summary. It discusses compliance with relevant laws and regulations, the legitimacy of incentive recipients, and the plan's alignment with company interests. There is no financial data, earnings information, or report publication. The content focuses on governance and management decisions related to stock incentives, which aligns with Board/Management Information filings that announce or explain management or board-level decisions and plans. The document length is short (1094 characters), and it is not an announcement of a report publication but an opinion on a management plan. Therefore, the most appropriate classification is Board/Management Information (MANG).
2015-07-20 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.